{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:29:25Z","timestamp":1761647365084},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.amjopharm.2005.07.001","type":"journal-article","created":{"date-parts":[[2005,8,30]],"date-time":"2005-08-30T11:59:55Z","timestamp":1125403195000},"page":"92-102","source":"Crossref","is-referenced-by-count":14,"title":["Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: A case-control study"],"prefix":"10.1016","volume":"3","author":[{"given":"Shaoli","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerrold","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2005.07.001_bib1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","article-title":"Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset","volume":"88","author":"Brookmeyer","year":"1998","journal-title":"Am J Public Health"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib2","first-page":"103","article-title":"Alzheimer's disease: Pathophysiology and the hope for therapy","volume":"87","author":"Brumback","year":"1994","journal-title":"J Okla State Med Assoc"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib3","first-page":"300","article-title":"The economic cost of Alzheimer's disease and related dementias to the California Medicaid program (\u201cMedi-Cal\u201d) in 1995","volume":"7","author":"Menzin","year":"1999","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1377\/hlthaff.17.6.206","article-title":"Alzheimer's disease care: Costs and potential savings","volume":"17","author":"Leon","year":"1998","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1532-5415.2000.tb04721.x","article-title":"How much do persons with Alzheimer's disease cost Medicare?","volume":"48","author":"Taylor","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2105\/AJPH.84.8.1261","article-title":"The US economic and social costs of Alzheimer's disease revisited","volume":"84","author":"Ernst","year":"1994","journal-title":"Am J Public Health"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1532-5415.2000.tb04720.x","article-title":"Predicting 10-year care requirements for older people with suspected Alzheimer's disease","volume":"48","author":"Kinosian","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1017\/S1041610292001066","article-title":"The effect of dementia on acute care in a geriatric medical unit","volume":"4","author":"Torian","year":"1992","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1532-5415.1999.tb05228.x","article-title":"Cost of Alzheimer's disease and related dementia in managed-Medicare","volume":"47","author":"Gutterman","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib10","first-page":"867","article-title":"The cost of Alzheimer's disease in managed care: A cross-sectional study","volume":"5","author":"Leon","year":"1999","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.58.1.62","article-title":"Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare","volume":"58","author":"Hill","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jama.1994.03510370037029","article-title":"A 30-week randomized control trial of high-dose tacrine in patients with Alzheimer's disease","volume":"271","author":"Knapp","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib15","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib16","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","article-title":"A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease","volume":"44","author":"Farlow","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.52.6.1138","article-title":"Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease","volume":"52","author":"Neumann","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib20","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0149-2918(00)80025-9","article-title":"The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model","volume":"21","author":"Jonsson","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1532-5415.1999.tb02572.x","article-title":"Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada","volume":"47","author":"O'Brien","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib22","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0149-2918(00)83053-2","article-title":"Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications","volume":"22","author":"Baladi","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00019053-200017040-00005","article-title":"Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine","volume":"17","author":"Hauber","year":"2000","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib24","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib25","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0149-2918(00)87246-X","article-title":"Donepezil use in managed Medicare: Effect on health care costs and utilization","volume":"21","author":"Fillit","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0149-2918(98)80145-8","article-title":"An economic evaluation of donepezil in the treatment of Alzheimer's disease","volume":"20","author":"Small","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib27","first-page":"63","article-title":"The effect of donepezil therapy on health costs in a Medicare managed care plan","volume":"15","author":"Hill","year":"2002","journal-title":"Manag Care Interface"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib28","series-title":"International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM)","author":"US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS)","year":"2003"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1046\/j.1532-5415.2001.49175.x","article-title":"Deriving a risk-adjustment model for pressure ulcer development using the Minimum Data Set","volume":"49","author":"Berlowitz","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib32","first-page":"113","article-title":"Nutritional risk factors for institutional placement in Alzheimer's disease after one year follow-up","volume":"5","author":"Andrieu","year":"2001","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00002093-199408030-00004","article-title":"Swallowing in Alzheimer's disease","volume":"8","author":"Horner","year":"1994","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib34","series-title":"Health Economics of Dementia","first-page":"327","article-title":"Severity scales","author":"Reisberg","year":"1998"},{"key":"10.1016\/j.amjopharm.2005.07.001_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000052811","article-title":"Risk factors of aspiration pneumonia in Alzheimer's disease patients","volume":"47","author":"Wada","year":"2001","journal-title":"Gerontology"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594605000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594605000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T17:26:04Z","timestamp":1548177964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594605000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1543594605000255"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2005.07.001","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}